{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:06:41Z","timestamp":1791576401402,"version":"4.3.4"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Nabriva Therapeutics AG"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant\n                    <jats:named-content content-type=\"genus-species\">Mycoplasma pneumoniae<\/jats:named-content>\n                    strains, and the results were compared with those of azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin testing. Lefamulin was highly active against all strains tested, with all MICs at \u22640.008 \u03bcg\/ml. The lefamulin MIC\n                    <jats:sub>90<\/jats:sub>\n                    (0.002 \u03bcg\/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.\n                  <\/jats:p>","DOI":"10.1128\/aac.02008-16","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T21:50:38Z","timestamp":1479160238000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":59,"title":["<i>In Vitro<\/i>\n                    Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China"],"prefix":"10.1128","volume":"61","author":[{"given":"Ken B.","family":"Waites","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Crabb","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn B.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-7435","authenticated-orcid":false,"given":"Jorgen S.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Sexually Transmitted Bacterial Infections, Research and Development, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University, and China Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Paukner","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics AG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.4.697-728.2004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2770"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.11.18"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02115648"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02060-12"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12666"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00706-13"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12107"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.066191-0"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00172510"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid\/1706.101558"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2108.150273"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00358-13"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00627-16"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks001"},{"key":"e_1_3_2_17_2","volume-title":"CLSI document M43-A","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Methods for Antimicrobial susceptibility testing of human mycoplasmas; approved guideline. CLSI document M43-A. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_18_2","volume-title":"Cumitech 34, laboratory diagnosis of mycoplasmal infections","author":"Waites KB","year":"2001","unstructured":"Waites KB BebearCMRobertsonJATalkingtonDFKennyGE. 2001. Cumitech 34, laboratory diagnosis of mycoplasmal infections. InNolteFS(coordinating ed). ASM Press,Washington, DC."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00090-09"},{"key":"e_1_3_2_20_2","first-page":"289","volume-title":"Mollicutes molecular biology and pathogenesis","author":"Waites KB","year":"2014","unstructured":"Waites KB LysynyanskyIBebearCM. 2014. Emerging antimicrobial resistance in mycoplasmas of humans and animals, p 289\u2013322. InBrowningGCittiC (ed), Mollicutes molecular biology and pathogenesis. Caister Academic Press,Norfolk, UK."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2001.0910"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0034-5288(97)90010-2"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.2010.02003.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02008-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02008-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:39:29Z","timestamp":1645457969000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02008-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1128\/AAC.02008-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02008-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"2016-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02008-16"}}